Abstract
Recently, we have cloned and characterized the Ras association domain family 1A gene (RASSF1A) at 3p21.3, from which loss of genetic material is one of the most frequent events in several types of human solid tumors. The CpG island promoter region of this gene is highly methylated in several human cancers, most notably in small cell lung cancer, breast cancer, and renal cell carcinoma. In this study, we have analysed the methylation status of RASSF1A in primary prostate tumors and in the prostate cancer cell line LNCaP. In total, 37 out of 52 tumors (71%) were methylated at the promoter region of RASSF1A. The relative frequency of methylation was higher in more aggressive tumors compared with less malignant tumors. For instance, tumors with a Gleason score of 7–10 (25 out of 30, 83%) were significantly more methylated compared with Gleason 4–6 tumors (11 out of 20, 55%, P=0.032, Fisher's exact test). Coincident with a hypermethylated promoter, transcripts of RASSF1A were missing in LNCaP cells. Expression of RASSF1A was restored with 5-aza-2′-deoxycytidine, a DNA methylation inhibitor. In conclusion, our data suggest that epigenetic inactivation of RASSF1A by methylation is a very common event in prostate cancer and might be involved in the progression of the disease. Testing for RASSF1A methylation should become useful in prostate cancer early detection and diagnosis and might aid prognosis by gauging the potential status of progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F . 2001 Oncogene 20: 1509–1518
Baylin SB, Herman JG . 2000 Trends Genet. 16: 168–174
Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD . 2001 J. Natl. Cancer Inst. 93: 691–699
Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, Chow NH, Grasso M, Wu L, Westra WB, Sidransky D . 2001 Clin. Cancer Res. 7: 2727–2730
Clark SJ, Harrison J, Paul CL, Frommer M . 1994 Nucleic Acids Res. 22: 2990–2997
Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR . 2001 Prostate 46: 249–256
Dahiya R, McCarville J, Hu W, Lee C, Chui RM, Kaur G, Deng G . 1997 Int. J. Cancer 71: 20–25
Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP . 2000 Nature Genet. 25: 315–319
Dammann R, Yang G, Pfeifer GP . 2001 Cancer Res. 61: 3105–3109
Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G, Zabarovsky ER . 2001 Proc. Natl. Acad. Sci. USA 98: 7504–7509
Elo JP, Visakorpi T . 2001 Ann. Med. 33: 130–141
Esteller M, Herman JG . 2002 J. Pathol. 196: 1–7
Goessl C, Muller M, Heicappell R, Krause H, Straub B, Schrader M, Miller K . 2001 Urology 58: 335–338
Gumerlock PH, Poonamallee UR, Meyers FJ, deVere White RW . 1991 Cancer Res. 51: 1632–1637
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826
Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK . 2001 J. Natl. Cancer Inst. 93: 824–842
Jones PA, Laird PW . 1999 Nature Genet. 21: 163–167
Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang X, Seed B, Avruch J . 2002 Curr. Biol. 12: 253–265
Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, Akakura K, Igarashi T, Nakayama T, Watanabe M, Harigaya K, Ito H . 2001 Prostate 49: 110–115
Kok K, Naylor SL, Buys CH . 1997 Adv. Cancer Res. 71: 27–92
Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG . 2001 Cancer Res. 61: 6688–6692
Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG . 1994 Proc. Natl. Acad. Sci. USA 91: 11733–11737
Lerman MI, Minna JD, Consortium fTILCCpTSG . 2000 Cancer Res. 60: 6116–6133
Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R . 2000 Cancer Res. 60: 702–706
Li LC, Zhao H, Nakajima K, Oh BR, Filho LA, Carroll P, Dahiya R . 2001 J. Urol. 166: 705–709
Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, Bova GS, Isaacs WB, Brooks JD, DeWeese TL, De Marzo AM, Nelson WG . 2001 Am. J. Pathol. 159: 1815–1826
Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang DP . 2001 Cancer Res. 61: 3877–3881
Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ . 2000 Cancer Res. 60: 944–949
Montgomery JS, Price DK, Figg WD . 2001 J. Pathol. 195: 138–146
Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y, Mizokami A, Ito H, Yatani R, Shiraishi T . 2000 Lab. Invest. 80: 1789–1796
Nelson JB, Lee WH, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG, Bova GS . 1997 Cancer Res. 57: 35–37
Nwosu V, Carpten J, Trent JM, Sheridan R . 2001 Hum. Mol. Genet. 10: 2313–2318
Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J . 2002 Oncogene 21: 1381–1390
Ostrander EA, Stanford JL . 2000 Am. J. Hum. Genet. 67: 1367–1375
Ozen M, Pathak S . 2000 Anticancer Res. 20: 1905–1912
Pao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA, Jones PA . 2001 Hum. Mol. Genet. 10: 903–910
Pfeifer GP, Steigerwald SD, Hansen RS, Gartler SM, Riggs AD . 1990 Proc. Natl. Acad. Sci. USA 87: 8252–8256
Rokman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J . 2001 Cancer Res. 61: 6038–6041
Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, Duh FM, Gazdar AF, Lerman MI, Minna JD . 1998 Oncogene 16: 3151–3157
Singal R, van Wert J, Bashambu M . 2001 Cancer Res. 61: 4820–4826
Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA . 2001 Nature Genet. 27: 172–180
Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ . 2000 J. Biol. Chem. 275: 35669–35672
Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN . 2001 Cancer Res. 61: 6494–6499
Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon III JW, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF, Minna JD . 2000 Cancer Res. 60: 1949–1960
Wu YQ, Chen H, Rubin MA, Wojno KJ, Cooney KA . 2001 Cancer Res. 61: 8651–8653
Xiong Z, Laird PW . 1997 Nucleic Acids Res. 25: 2532–2534
Yoon JH, Dammann R, Pfeifer GP . 2001 Int. J. Cancer 94: 212–217
Acknowledgements
We thank Steven Bates for culturing the LNCaP cells. This study was supported by a grant from the National Institutes of Health (CA88873) to GP Pfeifer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, L., Yoon, JH., Dammann, R. et al. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 21, 6835–6840 (2002). https://doi.org/10.1038/sj.onc.1205814
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205814
Keywords
This article is cited by
-
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
Nature Communications (2019)
-
Excess of a Rassf1-targeting microRNA, miR-193a-3p, perturbs cell division fidelity
British Journal of Cancer (2017)
-
Epigenetic modulators as therapeutic targets in prostate cancer
Clinical Epigenetics (2016)
-
Clinical utility of RASSF1A methylation in human malignancies
British Journal of Cancer (2015)